Glycolysis

Overview

Glycolysis is the most ancient and universal metabolic pathway, occurring in virtually every living cell. This ten-step enzymatic sequence takes place in the cytoplasm and converts one molecule of glucose (six carbons) into two molecules of pyruvate (three carbons each), with a net yield of two ATP and two NADH. Glycolysis does not require oxygen and can proceed under both aerobic and anaerobic conditions, making it the first line of energy production in all metabolic contexts.

Under aerobic conditions, pyruvate enters the mitochondria for further oxidation via the Krebs cycle and oxidative phosphorylation. Under anaerobic conditions, pyruvate is reduced to lactate (in animals) or ethanol (in yeast), regenerating NAD+ to sustain continued glycolytic flux.

How It Works

Investment Phase (Steps 1-5)

The first half of glycolysis consumes two ATP molecules to phosphorylate and rearrange glucose into two molecules of glyceraldehyde-3-phosphate (G3P):

1. Hexokinase — Glucose is phosphorylated to glucose-6-phosphate (costs 1 ATP)
2. Phosphoglucose isomerase — Glucose-6-phosphate is isomerized to fructose-6-phosphate
3. Phosphofructokinase-1 (PFK-1) — Fructose-6-phosphate is phosphorylated to fructose-1,6-bisphosphate (costs 1 ATP; rate-limiting step)
4. Aldolase — Fructose-1,6-bisphosphate is cleaved into dihydroxyacetone phosphate and G3P
5. Triose phosphate isomerase — Dihydroxyacetone phosphate is converted to G3P

Payoff Phase (Steps 6-10)

Each G3P molecule (two per glucose) is oxidized and converted to pyruvate, generating ATP and NADH:

6. Glyceraldehyde-3-phosphate dehydrogenase — G3P is oxidized (produces NADH)
7. Phosphoglycerate kinase — Substrate-level phosphorylation produces ATP
8. Phosphoglycerate mutase — Rearrangement step
9. Enolase — Dehydration creates phosphoenolpyruvate (PEP)
10. Pyruvate kinase — PEP transfers its phosphate to ADP, producing ATP and pyruvate

Net yield per glucose: 2 ATP, 2 NADH, 2 pyruvate.

Regulation

PFK-1 is the primary regulatory enzyme. It is activated by AMP, ADP, and fructose-2,6-bisphosphate (produced under insulin stimulation) and inhibited by ATP and citrate. Hexokinase is inhibited by its product glucose-6-phosphate, and pyruvate kinase is activated by fructose-1,6-bisphosphate (feed-forward activation) and inhibited by ATP and alanine.

Key Components

• Glucose — The six-carbon substrate entering the pathway
• ATP/ADP — Energy currency consumed and produced during glycolysis
• NAD+/NADH — Electron carrier oxidized and reduced during the payoff phase
• PFK-1 — The committed step enzyme and primary regulatory node
• Pyruvate — The three-carbon end product that connects to downstream pathways

Peptide Connections

Glycolysis is fundamentally regulated by hormonal peptides and influenced by mitochondria-derived signaling peptides:

Insulin is the master activator of glycolysis. When insulin binds its receptor, the downstream insulin signaling cascade stimulates glucose transporter (GLUT4) translocation to the cell surface, increasing glucose uptake. Insulin also activates PFK-2, which produces fructose-2,6-bisphosphate — the most potent activator of PFK-1. Additionally, insulin induces transcription of glucokinase and pyruvate kinase, upregulating glycolytic capacity in the liver.

MOTS-c is a mitochondria-derived peptide that enhances glucose metabolism through AMPK activation. By increasing AMPK activity, MOTS-c promotes glucose uptake and glycolytic flux while simultaneously improving the metabolic flexibility needed to coordinate glycolysis with downstream mitochondrial oxidation. Research in aged mice has demonstrated that MOTS-c administration improves glucose tolerance and insulin sensitivity, effects that depend partly on enhanced glycolytic regulation.

Glucagon opposes insulin's effects on glycolysis. In the liver, glucagon signaling via cAMP-dependent protein kinase A inhibits PFK-2 and pyruvate kinase, reducing glycolytic flux and redirecting substrates toward gluconeogenesis and glucose export into the blood.

Semaglutide and other GLP-1 receptor agonists potentiate insulin secretion and thereby indirectly enhance glycolytic activity in peripheral tissues. By improving beta-cell function and glucose-dependent insulin release, these peptides help normalize glycolytic regulation in individuals with type 2 diabetes.

Clinical Significance

Glycolytic dysregulation is central to several metabolic disorders. In type 2 diabetes, insulin resistance impairs glucose uptake and glycolytic activation, contributing to hyperglycemia. Conversely, cancer cells frequently exhibit upregulated glycolysis even in the presence of oxygen — a phenomenon known as the Warburg effect — to support rapid proliferation.

Inherited enzyme deficiencies in glycolysis (such as pyruvate kinase deficiency) cause hemolytic anemia, as red blood cells depend entirely on glycolysis for ATP production. Phosphofructokinase deficiency (Tarui disease) causes exercise intolerance and myopathy.

Related Topics

• Krebs Cycle — Receives pyruvate (as acetyl-CoA) for further oxidation
• Gluconeogenesis — The reverse pathway that synthesizes glucose from non-carbohydrate precursors
• Glycogen Metabolism — Storage and release of glucose for glycolytic input
• Insulin Signaling Cascade — Hormonal regulation of glycolytic activation
• Pentose Phosphate Pathway — Alternative glucose oxidation route branching from glycolytic intermediates